Eli Lilly and Company (NYSE:LLY ) Q2 2025 Earnings Conference Call August 7, 2025 8:30 AM ET Company Participants Daniel M. Skovronsky - EVP, Chief Scientific Officer and President of Lilly Research L

Jobless Claims Increased More Than Expected

12:20pm, Thursday, 07'th Aug 2025
Another full morning of market data to go through today, which will help articulate where we are in several accounts of the massive U.S. economy. Pre-market futures were at peak highs just ahead of ne
U.S. equities were mixed at midday as the market continued to focus on earnings, and new U.S. tariffs kicked in. The Nasdaq was up, while the Dow Jones Industrial Average and S&P 500 fell.
Pre-market futures were at peak highs just ahead of new economic prints this morning, but we remain in healthy, positive territory.
Eli Lilly & Co.'s new weight-loss pill had lower weight loss and higher rates of nausea and vomiting than anticipated in a study, according to the company. That news sent the stock plunging Thursday m

Eli Lilly shares drop despite Q2 beat

11:19am, Thursday, 07'th Aug 2025
CNBC's Angelica Peebles joins 'Squawk on the Street' to discuss the latest earnings from drugmaker Eli Lilly.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Although the revenue and EPS for Lilly (LLY) give a sense of how its business performed in the quarter ended June 2025, it might be worth considering how some key metrics compare with Wall Street esti
Ely Lilly (LLY) shares sank 14% Thursday when the pharmaceutical firm reported disappointing results from a late-stage study of its experimental obesity pill. The news offset Lilly's strong quarterly
On Thursday, Eli Lilly and Co.'s LLY weight loss rival Novo Nordisk A/S NVO, along with smaller firms, Terns Pharmaceuticals, Inc. TERN, Viking Therapeutics Inc. VKTX, and Structure Therapeutics Inc.
Eli Lilly and Co (NYSE:LLY) shares fell more than 10% at the market open as disappointing late-stage trial data for the company's oral weight loss drug orforglipron drew focus from strong second quart
Eli Lilly's (LLY) earnings beat wasn't enough draw investors in. The bigger focus was on the company's weight loss pill that showed "disappointing" results.
Eli Lilly (LLY) came out with quarterly earnings of $6.31 per share, beating the Zacks Consensus Estimate of $5.61 per share. This compares to earnings of $3.92 per share a year ago.
CNBC's Angelica Peebles and Eli Lilly chairman and CEO David Ricks join 'Squawk Box' to discuss the company's quarterly earnings results, late-stage trial data on its experimental obesity pill orforgl
CNBC's Angelica Peebles joins 'Squawk Box' with the latest news from Eli Lilly.
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE